An interventional study of BUFY01 eye drops in single-dose containers and SVS20 eye drops in single-dose containers in Dry Eye Disease, sponsored by TRB Chemedica International SA. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by TRB Chemedica International SA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.
Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 21st largest by planned enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2026, is one of 28 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 33rd registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
TRB Chemedica International SA · Sites in France, Austria
Ages 18+
AbbVie · Sites in France, United States, Netherlands
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Essilor International · Sites in France
Ages 4+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 81 across the 40 interventional studies, 45 across the 7 observational. Of the 29 that completed or were terminated, 12 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 47 have an industry lead sponsor. The 10 most frequent:
TRB Chemedica International SA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
TRB Chemedica International SA has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies in Dry Eye Syndromes with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03358979Fondation Ophtalmologique Adolphe de RothschildThree-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) | 2026-12 |
| NCT05865379TRB Chemedica International SAEfficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT05865457TRB Chemedica International SAEfficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 47 studies in Dry Eye Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:
Participants will be asked to:
Researchers will compare BUFY01 to SVS20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria includes:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0.18% Sodium Hyaluronate (trometamol buffer) in single-dose containers of 0.3 mL
Device: BUFY01 eye drops in single-dose containers
0.18% Sodium Hyaluronate (phosphate buffer) in single-dose containers of 0.3 mL
Device: SVS20 eye drops in single-dose containers
1 to 2 drops in each eye, as often as needed
1 to 2 drops in each eye, as often as needed
Signs
Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome)
Time frame: Day 28
Symptoms
Change from baseline in Ocular Surface Disease Index
Time frame: Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.
Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 6 months is below that.
Counting every sponsor, half of 314 studies reached it within 10 months; a quarter within 4 and three quarters within 18.
Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TRB Chemedica International SA